Neuphoria Therapeutics (NEUP) Change in Accured Expenses (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Change in Accured Expenses of -$1.2 million for Q1 2026, down 414.08% year-over-year from $375529.0 in Q1 2025, and up 26.41% quarter-over-quarter from -$1.6 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Change in Accured Expenses for 4 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 414.08% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $201135.0 (up 171.96% YoY), while the FY2025 annual figure was $1.5 million, up 435.05% from the prior year.
- Change in Accured Expenses grew to -$1.2 million in Q1 2026 per NEUP's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.3 million in Q2 2025 and bottomed at -$1.6 million in Q4 2025.
- Historically, Change in Accured Expenses has averaged -$27222.1 across 4 years, with a median of -$367583.0 in 2024.
- Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 354.01% — and 2026, when it sank 414.08%.
- Neuphoria Therapeutics' Change in Accured Expenses stood at $957800.0 in 2023, then slumped by 182.1% to -$786378.0 in 2024, then plunged by 103.81% to -$1.6 million in 2025, then rose by 26.41% to -$1.2 million in 2026.
- Business Quant data shows NEUP's Change in Accured Expenses at -$1.2 million in Q1 2026, -$1.6 million in Q4 2025, and $718261.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | -1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.18 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Sep 30, 2025 | 718,261.00 |
| Sep 30, 2025 | 718,261.00 |
| Jun 30, 2025 | 2.27 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 375,529.00 |
| Mar 31, 2025 | 375,529.00 |
| Dec 31, 2024 | -786,378.00 |
| Dec 31, 2024 | -786,378.00 |
| Sep 30, 2024 | -367,583.00 |
| Sep 30, 2024 | -367,583.00 |
| Jun 30, 2024 | 498,908.00 |
| Jun 30, 2024 | 498,908.00 |
| Mar 31, 2024 | -474,109.00 |
| Mar 31, 2024 | -474,109.00 |
| Dec 31, 2023 | 957,800.00 |
| Dec 31, 2023 | 957,800.00 |